Evaluation Of Serratia Peptidase In Acute Or Chronic Inflammation Of Otorhinolaryngology Pathology: A Multicentre, Double-blind, Randomized Trial Versus Placebo
Notes for this study:
|Number of Subjects
||18-29, 30-44, 45-64, 65+
In persons with acute or chronic ear, nose or throat disorders given 10mg of serrapeptase thrice daily (30mg total), supplementation was more effective than placebo in reducing abnormalities of mucus production and swallowing and was also analgesic.